David Finn, Co-Founder of a Public Relations Power, Dies at 100 [The New York Times]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: The New York Times
Business|David Finn, Co-Founder of a Public Relations Power, Dies at 100https://www.nytimes.com//10/19/business/david-finn-dead.htmlmentContinue reading the main storySupported byWhile running Ruder Finn, with big clients like Philip Morris, Exxon and Coca-Cola, Mr. Finn pursued a parallel career as a painter, photographer and sculptor.Credit...ByGlenn RifkinOct. 19, ,3:23 p.m. ETDavid Finn, a dominant figure in the creation of the modern public relations industry as the co-founder of Ruder Finn, one of the most successful corporate P.R. firms to emerge after World War II, died on Monday at his home in New Rochelle, N.Y. He was 100.His granddaughter Rachel Spielman said the cause was atherosclerotic cerebrovascular disease, which results from a thickening and hardening of the walls of the arteries in the brain.Mr. Finn was a public relations counsel to such corporate giants as Lever Brothers, Exxon, Bristol-Myers Squibb, Novartis and Coca-Cola. He was also devoted to the arts as a pai
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb: The Comeback Is Unfolding [Seeking Alpha]Seeking Alpha
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… [YahoYaho
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…Business Wire
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s DiseaseBusiness Wire
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 3/28/24 - Form DEFA14A
- 3/28/24 - Form DEF
- 3/28/24 - Form ARS
- BMY's page on the SEC website